OBJECTIVES: To evaluate the association of thrombin-activatable fibrinolysis inhibitor (TAFI) gene polymorphisms with the risk of coronary heart disease (CHD) and with TAFI levels measured by a newly developed enzyme-linked immunosorbent assay (ELISA) (TAFI-1B1), shown to be a reliable method for detecting quantitative variations in circulating TAFI. PATIENTS/ METHODS: Six polymorphisms (C-2599G, G-438A, Ala147Thr, Thr325Ile, C + 1542G and T + 1583A) were genotyped and baseline plasma concentrations of TAFI were measured in a nested case-control design as part of the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Participants from France and Northern Ireland who had developed a CHD event during a 5-year follow-up (n = 321) were compared with 645 population- and age-matched control subjects. RESULTS: In France, the Thr147 allele was more frequent in cases than in controls (0.41 vs. 0.32; P = 0.02), whereas the reverse was observed in Northern Ireland (0.33 vs. 0.38; P = 0.19) (P = 0.01 for interaction). No other polymorphism was associated with CHD risk. Consistent with the results derived from the single-locus analysis, haplotype analysis revealed that the haplotype carrying the Thr147 allele was associated with increased risk of CHD in France while the reverse tended to hold in the Northern Ireland population. Single-locus and haplotype analyses revealed that two polymorphisms, C-2599G and Ala147Thr (or T + 1583A that is in nearly complete association with it), had additive effects on TAFI levels and explained >18% of TAFI variability. This effect was homogeneous in France and Northern Ireland, and in cases and controls who exhibited similar TAFI levels. CONCLUSIONS: Thrombin-activatable fibrinolysis inhibitor gene polymorphisms are strongly associated to plasma TAFI levels, but the relation to CHD risk is less clear.
OBJECTIVES: To evaluate the association of thrombin-activatable fibrinolysis inhibitor (TAFI) gene polymorphisms with the risk of coronary heart disease (CHD) and with TAFI levels measured by a newly developed enzyme-linked immunosorbent assay (ELISA) (TAFI-1B1), shown to be a reliable method for detecting quantitative variations in circulating TAFI. PATIENTS/ METHODS: Six polymorphisms (C-2599G, G-438A, Ala147Thr, Thr325Ile, C + 1542G and T + 1583A) were genotyped and baseline plasma concentrations of TAFI were measured in a nested case-control design as part of the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study. Participants from France and Northern Ireland who had developed a CHD event during a 5-year follow-up (n = 321) were compared with 645 population- and age-matched control subjects. RESULTS: In France, the Thr147 allele was more frequent in cases than in controls (0.41 vs. 0.32; P = 0.02), whereas the reverse was observed in Northern Ireland (0.33 vs. 0.38; P = 0.19) (P = 0.01 for interaction). No other polymorphism was associated with CHD risk. Consistent with the results derived from the single-locus analysis, haplotype analysis revealed that the haplotype carrying the Thr147 allele was associated with increased risk of CHD in France while the reverse tended to hold in the Northern Ireland population. Single-locus and haplotype analyses revealed that two polymorphisms, C-2599G and Ala147Thr (or T + 1583A that is in nearly complete association with it), had additive effects on TAFI levels and explained >18% of TAFI variability. This effect was homogeneous in France and Northern Ireland, and in cases and controls who exhibited similar TAFI levels. CONCLUSIONS:Thrombin-activatable fibrinolysis inhibitor gene polymorphisms are strongly associated to plasma TAFI levels, but the relation to CHD risk is less clear.
Authors: Maria Sabater-Lleal; Alfonso Buil; Juan Carlos Souto; Laura Alamsy; Montserrat Borrell; Mark Lathrop; John Blangero; Jordi Fontcuberta; José Manuel Soria Journal: Hum Genet Date: 2008-06-18 Impact factor: 4.132
Authors: Wolfgang Lieb; Tanja Zeller; Massimo Mangino; Anika Götz; Peter Braund; Juergen J Wenzel; Christian Horn; Carole Proust; Patrick Linsel-Nitschke; Philippe Amouyel; Petra Bruse; Dominique Arveiler; Inke R König; Jean Ferrières; Andreas Ziegler; Anthony J Balmforth; Alun Evans; Pierre Ducimetière; Francois Cambien; Christian Hengstenberg; Klaus Stark; Alistair S Hall; Heribert Schunkert; Stefan Blankenberg; Nilesh J Samani; Jeanette Erdmann; Laurence Tiret Journal: J Mol Med (Berl) Date: 2008-07-01 Impact factor: 4.599
Authors: Mirjam E Meltzer; Carine J M Doggen; Philip G de Groot; Joost C M Meijers; Frits R Rosendaal; Ton Lisman Journal: Haematologica Date: 2009-04-18 Impact factor: 9.941
Authors: Yaakov Bentov; Theodore J Brown; Mohammad R Akbari; Robert Royer; Harvey Risch; Barry Rosen; John McLaughlin; Ping Sun; Shiyu Zhang; Steven A Narod; Robert F Casper Journal: PLoS One Date: 2009-06-15 Impact factor: 3.240
Authors: Tara M Stanne; Maja Olsson; Erik Lorentzen; Annie Pedersen; Anders Gummesson; Ann Gils; Katarina Jood; Gunnar Engström; Olle Melander; Paul J Declerck; Christina Jern Journal: Thromb Haemost Date: 2018-01-29 Impact factor: 5.249
Authors: Irma Isordia-Salas; Manuel Martínez-Marino; Paolo Alberti-Minutti; María Tania Ricardo-Moreno; Ricardo Castro-Calvo; David Santiago-Germán; José Antonio Alvarado-Moreno; Cristian Calleja-Carreño; Jesús Hernández-Juárez; Alfredo Leaños-Miranda; Abraham Majluf-Cruz Journal: Dis Markers Date: 2019-10-30 Impact factor: 3.434